Search company, investor...

Total Raised

$97.35M

Investors Count

13

Deal Terms

2

Funding, Valuation & Revenue

4 Fundings

Bayhill Therapeutics has raised $97.35M over 4 rounds.

Bayhill Therapeutics's latest funding round was a Dead for on June 11, 2011.

Bayhill Therapeutics's valuation in July 2002 was $34.02M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

6/11/2011

Dead

Dead

$99M

0

FY undefined

7/15/2009

Series C

$99M

$99M

0

FY undefined

0

12/21/2007

Series B

$99M

$99M

0

FY undefined

0

7/10/2002

Series A

$99M

$34.02M

0

FY undefined

0

Date

6/11/2011

7/15/2009

12/21/2007

7/10/2002

Round

Dead

Series C

Series B

Series A

Amount

$99M

$99M

$99M

Investors

Dead

Valuation

$99M

$99M

$99M

$34.02M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

0

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Bayhill Therapeutics Deal Terms

2 Deal Terms

Bayhill Therapeutics's deal structure is available for 2 funding rounds, including their Series B from December 21, 2007.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Bayhill Therapeutics Investors

13 Investors

Bayhill Therapeutics has 13 investors. Morgenthaler Ventures invested in Bayhill Therapeutics's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/10/2002

7/15/2009

3
Series A, Series B (2007), Series C (2009)

Venture Capital

California

7/10/2002

7/15/2009

3
Series A, Series B (2007), Series C (2009)

Venture Capital

California

7/10/2002

7/15/2009

3
Series A, Series B (2007), Series C (2009)

Patrick Latterell, and James Woody

Venture Capital

California

00/00/0000

00/00/0000

The Vertical Group

Subscribe to see more

Venture Capital

New Jersey

00/00/0000

00/00/0000

U.S. Venture Partners

Subscribe to see more

Venture Capital

California

First funding

7/10/2002

7/10/2002

7/10/2002

00/00/0000

00/00/0000

Last Funding

7/15/2009

7/15/2009

7/15/2009

00/00/0000

00/00/0000

Investor

The Vertical Group

U.S. Venture Partners

Rounds

3
Series A, Series B (2007), Series C (2009)
3
Series A, Series B (2007), Series C (2009)
3
Series A, Series B (2007), Series C (2009)

Subscribe to see more

Subscribe to see more

Board Seats

Patrick Latterell, and James Woody

Type

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Location

California

California

California

New Jersey

California

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Bayhill Therapeutics to Competitors

REGiMMUNE Logo
REGiMMUNE

REGiMMUNE is a biotechnology company focused on the development of novel medicines for immune disorders. The company's main offerings include treatments designed to modulate the immune system and harness a patient's own immune response for inducing tolerance and achieving anti-tumor effects. These therapies are aimed at a range of immune-related conditions. It was founded in 2006 and is based in Tokyo, Japan.

S
Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

D
Dare Bioscience

Dare Bioscience operates a healthcare company. Its commitment is to develop and commercialize innovative products in women's reproductive health. Dare Bioscience was formerly known as Tempo Pharmaceuticals. The company was founded in 2005 and is based in San Diego, California.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

D
Decimmune Therapeutics

Decimmune Therapeutics focuses on the development of therapeutic antibodies in the biotechnology sector. The company's main product, a novel monoclonal antibody, is designed to prevent tissue damage and preserve organ function in various vascular inflammatory diseases. The primary market for Decimmune Therapeutics includes the healthcare sector, specifically targeting the treatment of vascular inflammatory conditions. It was founded in 2001 and is based in Cambridge, Massachusetts.

L
LeukoSight

LeukoSight is a biopharmaceutical company focused on developing anti-inflammatory therapeutics for autoimmune and inflammatory diseases. The company's main innovation involves reprogramming white blood cells to secrete immunoregulatory molecules, aiming to create treatments that are potentially less toxic and more effective than current options. LeukoSight's primary market includes sectors dealing with multiple sclerosis and other autoimmune/inflammatory conditions. It is based in Columbia, Maryland.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.